Association of CYP2C19*2/3 gene polymorphism with lung cancer in Moroccan population

被引:0
|
作者
Berradi, Hind [1 ]
Kaanane, Houda [1 ]
Hassani Idrissi, Hind [1 ]
Elkadmiri, Nadia [3 ]
Benchakroun, Nadia [2 ]
Benider, Abdellatif [2 ]
Izaabel, El Hassan [4 ]
Nadifi, Sellama [1 ]
机构
[1] Hassan II Univ Casablanca, Fac Med & Pharm, Lab Cellular & Mol Pathol, BP 9154, Casablanca, Morocco
[2] CHU Ibn Rochd, Mohamed VI Ctr Canc Treatment, Anat Pathol Serv, Casablanca, Morocco
[3] IBN ZOHR Univ, Fac Polydisciplinaire Taroudant, BP 271, Taroudant 83000, Morocco
[4] Univ Ibn Zohr, Fac Sci, Cellular Biol & Mol Genet Lab, Agadir, Morocco
来源
GENE REPORTS | 2021年 / 25卷
关键词
CYP2C19*2; Cyp2c19*3; Lung cancer; Smoking; Predisposition; POOR METABOLIZERS; INCREASED RISK; CYP2C19; 2C19;
D O I
10.1016/j.genrep.2021.101314
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: As it is the case for all kinds of cancer; lung cancer is a multifactorial disease. The interaction between both Exposures to different carcinogens and individual genetic backgrounds modulate the disease risk. Cytochrome P450 family is one of the main enzymes involved in the metabolism of these carcinogens. Therefore, polymorphisms of genes encoding for the cyp450 enzymes can be responsible for the inter-individual differences in lung cancer susceptibility. In this study, we chose to focus on the Cyp2c19, as one of the crucial cyp450 enzymes associated with metabolism of a number of drugs and xenobiotics and its association with the lung cancer risk. Methods: Peripheral blood from a total of 115 Moroccan patients diagnosed with lung cancer and 105 healthy subjects was collected. The genotyping of CYP2C19*2 and CYP2C19*3 polymorphisms was carried out using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technic. Results: We found that the frequency of both CYP2C19*2 (GA+AA) genotype and CYP2C19*A allele were significantly more frequent in lung cancer patients than that in control subjects (24.3% vs 13.3%; p = 0.04 and 14.35% vs 7.15%; p = 0.01 respectively). We also found that the CYP2C19*3 A allele was only found in lung cancer patient with a frequency of 10% (p = 0.007). Consequently, the frequency of the CYP2C19*3 (GA + AA) genotype was also significantly more prevalent in lung cancer patients than that in controls (20% vs 0.00%; p = 0.005). We also found that smoking is associated to a higher lung cancer risk in participants carrying CYP2C19*3 or CYP2C19*2 GG genotypes (p < 0.0001, OR = 26.42, 95%CI = 12.38-56.36) and (p < 0.0001, OR = 24,44, 95%CI = 11,13-53,65). While the binary logistic regression analysis demonstrates that interaction of CYP2C19*2 with smoking has no effect on the lung cancer risk, unlike the CYP2C19*3 which coexisted with smoking increases lung cancer risk even more. Conclusion: These findings indicate that the CYP2C19*2 and CYP2C19*3 polymorphisms are significantly associated with lung cancer in Moroccan population. In addition, that the coexistence of CYP2C19*3 with smoking increased lung cancer risk even more.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Functional evaluation of CYP2C19 and CYP3A4 gene polymorphism on ibuprofen metabolism
    Yuan, Ling-Jing
    Li, Xiang-Yu
    Ni, Jin-Huan
    Wang, Jing
    Xu, Xiao-Yu
    Luo, Jian-Chao
    Zhou, Qi
    Hu, Guo-Xin
    Cai, Jian-Ping
    Qian, Jian-Chang
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2023, 475
  • [32] Correlation of CYP2C19 gene polymorphism and coronary heart disease in Yunnan Han population
    Zhang Liguo
    Zhuo Yu
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 64 (16) : C243 - C243
  • [33] Frequency of CYP2C19 Gene Polymorphism in Stented Patients: Review
    Taizhanova, Dana
    Toleuova, Aliya
    Bodaubai, Roza
    Kalimbetova, Akerke
    Kurmanova, Aigul
    Turmuhambetova, Anar
    Babenko, Dmitriy
    Chesca, Antonella
    PROCEEDINGS OF THE 35TH BALKAN MEDICAL WEEK, 2018, : 156 - 159
  • [34] In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease
    Ohnishi, A
    Murakami, S
    Akizuki, S
    Mochizuki, J
    Echizen, H
    Takagi, I
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (11): : 1221 - 1229
  • [35] Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy
    Tantray, Javeed Ahmad
    Reddy, K. Pratap
    Jamil, Kaiser
    Kumar, Y. Shiva
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 229 : 113 - 118
  • [36] Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population
    Jónrit Halling
    Maria S. Petersen
    Per Damkier
    Flemming Nielsen
    Philippe Grandjean
    Pál Weihe
    Stefan Lundgren
    Mia Sandberg Lundblad
    Kim Brøsen
    European Journal of Clinical Pharmacology, 2005, 61 : 491 - 497
  • [37] Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population
    Halling, J
    Petersen, M
    Damkier, P
    Nielsen, F
    Grandjean, P
    Weihe, P
    Lundgren, S
    Lundblad, M
    Brosen, K
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (07) : 491 - 497
  • [38] Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study
    Heydy V. Bravo-Villalta
    Koujirou Yamamoto
    Katsunori Nakamura
    Ana Bayá
    Yuko Okada
    Ryuya Horiuchi
    European Journal of Clinical Pharmacology, 2005, 61 : 179 - 184
  • [39] The participation of CYP2C19 gene mutation in liver cancer
    Nishimura, Yuki
    Kurata, Norimitsu
    Iwase, Mariko
    Kobayashi, Yasuna
    Yamamoto, Toshinori
    Yasuhara, Hajime
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 : 285P - 285P
  • [40] Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population:: an investigative and comparative study
    Bravo-Villalta, HV
    Yamamoto, K
    Nakamura, K
    Bayá, A
    Okada, Y
    Horiuchi, R
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (03) : 179 - 184